Literature DB >> 29419431

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.

Haneen Shalabi1, Ira L Kraft1, Hao-Wei Wang2, Constance M Yuan2, Bonnie Yates1, Cindy Delbrook1, Julie D Zimbelman3, Roger Giller4, Maryalice Stetler-Stevenson2, Elaine S Jaffe2, Daniel W Lee5, Jack F Shern1, Terry J Fry1, Nirali N Shah6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29419431      PMCID: PMC5927974          DOI: 10.3324/haematol.2017.183459

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Authors:  Rebecca Gardner; David Wu; Sindhu Cherian; Min Fang; Laïla-Aïcha Hanafi; Olivia Finney; Hannah Smithers; Michael C Jensen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

2.  Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.

Authors:  Hui Yu; Elena Sotillo; Colleen Harrington; Gerald Wertheim; Michele Paessler; Shannon L Maude; Susan R Rheingold; Stephan A Grupp; Andrei Thomas-Tikhonenko; Vinodh Pillai
Journal:  Am J Hematol       Date:  2016-11-21       Impact factor: 10.047

3.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

4.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

5.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

6.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

7.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

8.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Authors:  James N Kochenderfer; Robert P T Somerville; Tangying Lu; Victoria Shi; Adrian Bot; John Rossi; Allen Xue; Stephanie L Goff; James C Yang; Richard M Sherry; Christopher A Klebanoff; Udai S Kammula; Marika Sherman; Arianne Perez; Constance M Yuan; Tatyana Feldman; Jonathan W Friedberg; Mark J Roschewski; Steven A Feldman; Lori McIntyre; Mary Ann Toomey; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

Review 9.  Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science.

Authors:  Jessica Hochberg; Ian M Waxman; Kara M Kelly; Erin Morris; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2009-01       Impact factor: 6.998

10.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

View more
  65 in total

Review 1.  Treatment resistance in diffuse large B-cell lymphoma.

Authors:  Michael Y He; Robert Kridel
Journal:  Leukemia       Date:  2021-05-20       Impact factor: 11.528

Review 2.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

3.  CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm.

Authors:  LaQuisa Hill; Premal Lulla; Helen E Heslop
Journal:  Adv Cell Gene Ther       Date:  2019-03-28

Review 4.  The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Authors:  Peter Braendstrup; Bruce L Levine; Marco Ruella
Journal:  Cytotherapy       Date:  2020-02-01       Impact factor: 5.414

Review 5.  The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?

Authors:  Domenico Galati; Serena Zanotta; Marialuisa Bocchino; Rosaria De Filippi; Antonio Pinto
Journal:  Cancer Immunol Immunother       Date:  2021-01-01       Impact factor: 6.968

6.  Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.

Authors:  Wai-Hang Leung; Joel Gay; Unja Martin; Tracy E Garrett; Holly M Horton; Michael T Certo; Bruce R Blazar; Richard A Morgan; Philip D Gregory; Jordan Jarjour; Alexander Astrakhan
Journal:  JCI Insight       Date:  2019-04-30

Review 7.  Immunotherapy of lymphomas.

Authors:  Stephen M Ansell; Yi Lin
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

8.  Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.

Authors:  Jingsheng Hua; Jian Zhang; Xinyou Zhang; Xiaoxia Wu; Lili Zhou; Xiebing Bao; Yue Han; Miao Miao; Caixia Li; Chengcheng Fu; Suning Chen; Xiaowen Tang; Depei Wu; Huiying Qiu
Journal:  Bone Marrow Transplant       Date:  2020-11-24       Impact factor: 5.483

9.  Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.

Authors:  Gerald P Linette; Michelle Becker-Hapak; Zachary L Skidmore; Miren Lorea Baroja; Chong Xu; Jasreet Hundal; David H Spencer; Weixuan Fu; Casey Cummins; Maya Robnett; Saghar Kaabinejadian; William H Hildebrand; Vincent Magrini; Ryan Demeter; Alexander S Krupnick; Obi L Griffith; Malachi Griffith; Elaine R Mardis; Beatriz M Carreno
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-04       Impact factor: 11.205

10.  CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

Authors:  Nirali N Shah; Steven L Highfill; Haneen Shalabi; Bonnie Yates; Jianjian Jin; Pamela L Wolters; Amanda Ombrello; Seth M Steinberg; Staci Martin; Cindy Delbrook; Leah Hoffman; Lauren Little; Anusha Ponduri; Haiying Qin; Haris Qureshi; Alina Dulau-Florea; Dalia Salem; Hao-Wei Wang; Constance Yuan; Maryalice Stetler-Stevenson; Sandhya Panch; Minh Tran; Crystal L Mackall; David F Stroncek; Terry J Fry
Journal:  J Clin Oncol       Date:  2020-04-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.